Chunjing Yu1, Donghui Pan2, Baoming Mi1, Yuping Xu2, Lixin Lang3, Gang Niu3, Min Yang4, Weixing Wan5, Xiaoyuan Chen6. 1. Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi No. 4 People's Hospital), Wuxi, China. 2. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China. 3. Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA. 4. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China. ymzfk@yahoo.com.hk. 5. Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi No. 4 People's Hospital), Wuxi, China. wwxjs@126.com. 6. Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA. shawn.chen@nih.gov.
Abstract
PURPOSE: We report the biodistribution and radiation dosimetry of an integrin αvβ3 specific PET tracer (18)F-AlF-NOTA-E[PEG4-c(RGDfk)]2) (denoted as (18)F-Alfatide II). We also assessed the value of (18)F-Alfatide II in patients with brain metastases. METHODS: A series of torso (from the skull to the thigh) static images were acquired in five healthy volunteers (3 M, 2 F) at 5, 10, 15, 30, 45, and 60 min after injection of (18)F-Alfatide II (257 ± 48 MBq). Regions of interest (ROIs) were drawn manually, and the time-activity curves (TACs) were obtained for major organs. Nine patients with brain metastases were examined by static PET imaging with (18)F-FDG (5.55 MBq/kg) and (18)F-Alfatide II. RESULTS: Injection of (18)F-Alfatide II was well tolerated in all healthy volunteers, with no serious tracer-related adverse events found. (18)F-Alfatide II showed rapid clearance from the blood pool and kidneys. The total effective dose equivalent (EDE) and effective dose (ED) were 0.0277 ± 0.003 mSv/MBq and 0.0198 ± 0.002 mSv/MBq, respectively. The organs with the highest absorbed dose were the kidneys and the spleen. Nine patients with 20 brain metastatic lesions identified by MRI and/or CT were enrolled in this study. All 20 brain lesions were visualized by (18)F-Alfatide II PET, while only ten lesions were visualized by (18)F-FDG, and 13 by CT. CONCLUSION: F-Alfatide II is a safe PET tracer with a favorable dosimetry profile. The observed ED suggests that (18)F-Alfatide II is feasible for human studies. (18)F-Alfatide II has potential value in finding brain metastases of different cancers as a biomarker of angiogenesis.
PURPOSE: We report the biodistribution and radiation dosimetry of an integrin αvβ3 specific PET tracer (18)F-AlF-NOTA-E[PEG4-c(RGDfk)]2) (denoted as (18)F-Alfatide II). We also assessed the value of (18)F-Alfatide II in patients with brain metastases. METHODS: A series of torso (from the skull to the thigh) static images were acquired in five healthy volunteers (3 M, 2 F) at 5, 10, 15, 30, 45, and 60 min after injection of (18)F-Alfatide II (257 ± 48 MBq). Regions of interest (ROIs) were drawn manually, and the time-activity curves (TACs) were obtained for major organs. Nine patients with brain metastases were examined by static PET imaging with (18)F-FDG (5.55 MBq/kg) and (18)F-Alfatide II. RESULTS: Injection of (18)F-Alfatide II was well tolerated in all healthy volunteers, with no serious tracer-related adverse events found. (18)F-Alfatide II showed rapid clearance from the blood pool and kidneys. The total effective dose equivalent (EDE) and effective dose (ED) were 0.0277 ± 0.003 mSv/MBq and 0.0198 ± 0.002 mSv/MBq, respectively. The organs with the highest absorbed dose were the kidneys and the spleen. Nine patients with 20 brain metastatic lesions identified by MRI and/or CT were enrolled in this study. All 20 brain lesions were visualized by (18)F-Alfatide II PET, while only ten lesions were visualized by (18)F-FDG, and 13 by CT. CONCLUSION: F-Alfatide II is a safe PET tracer with a favorable dosimetry profile. The observed ED suggests that (18)F-Alfatide II is feasible for human studies. (18)F-Alfatide II has potential value in finding brain metastases of different cancers as a biomarker of angiogenesis.
Authors: Jason L J Dearling; Jessica W Barnes; Dipak Panigrahy; Robert E Zimmerman; Frederic Fahey; S Ted Treves; Matthew S Morrison; Mark W Kieran; Alan B Packard Journal: Nucl Med Biol Date: 2013-05-20 Impact factor: 2.408
Authors: Ambros J Beer; Sylvie Lorenzen; Stephan Metz; Ken Herrmann; Petra Watzlowik; Hans-Jürgen Wester; Christian Peschel; Florian Lordick; Markus Schwaiger Journal: J Nucl Med Date: 2007-12-12 Impact factor: 10.057
Authors: Xiaoyuan Chen; Ryan Park; Anthony H Shahinian; Michel Tohme; Vazgen Khankaldyyan; Mohammed H Bozorgzadeh; James R Bading; Rex Moats; Walter E Laug; Peter S Conti Journal: Nucl Med Biol Date: 2004-02 Impact factor: 2.408
Authors: Tuo Shao; Zhen Chen; Vasily Belov; Xiaohong Wang; Steve H Rwema; Viksit Kumar; Hualong Fu; Xiaoyun Deng; Jian Rong; Qingzhen Yu; Lixin Lang; Wenyu Lin; Lee Josephson; Anthony E Samir; Xiaoyuan Chen; Raymond T Chung; Steven H Liang Journal: J Hepatol Date: 2020-03-05 Impact factor: 25.083